What Happened
- GLP-1 receptor agonist drugs — primarily semaglutide (sold under brand names Ozempic for diabetes and Wegovy for obesity) — are at the centre of a global health and policy debate following a surge in their use as weight-loss treatments.
- In India, the semaglutide patent expired on March 20, 2026, triggering an immediate wave of generic launches. Over 40 Indian pharmaceutical companies are expected to launch 50+ generic versions.
- At least five major Indian companies — including Dr. Reddy's, Zydus, Alkem, Sun Pharma, and Glenmark — have already launched generics priced 70–80% below Novo Nordisk's branded product, with monthly costs ranging from ₹1,800 to ₹4,200.
- Indian regulators (CDSCO) issued guidelines and advisories in March 2026 restricting GLP-1 drug prescriptions to endocrinologists, internal medicine specialists, and cardiologists — not general physicians.
- A central government directive on March 24, 2026 flagged concerns about unauthorised sales, misleading promotion, and off-label use for cosmetic weight loss.
- The government inspected 49 businesses — including online pharmacy warehouses, drug wholesalers, retailers, and weight loss clinics — for violations.
- A PIB document (April 1, 2026) outlined the government's regulatory framework for GLP-1 drugs, flagging risks and prescribing norms.
- The key policy question: with generic semaglutide now available at relatively low cost, should public health schemes like Ayushman Bharat PM-JAY cover GLP-1 drugs for obesity — a growing NCD burden?
Static Topic Bridges
GLP-1 Receptor Agonists — Mechanism and Significance
Glucagon-Like Peptide-1 (GLP-1) receptor agonists are a class of drugs that mimic the action of incretin hormones — gut-derived hormones released after eating that stimulate insulin secretion, suppress glucagon, slow gastric emptying, and signal satiety to the brain. Originally developed for Type 2 diabetes management, they were found to produce significant weight loss as a side effect. Clinical trials (STEP, SUSTAIN, SELECT trials) demonstrated that semaglutide reduces body weight by 10–15% on average and, importantly, also reduces cardiovascular event risk in people with obesity. This combination of metabolic benefits has driven their explosive global demand.
- Key drugs: Semaglutide (Ozempic/Wegovy — Novo Nordisk), Liraglutide (Victoza/Saxenda — Novo Nordisk), Tirzepatide (Mounjaro/Zepbound — Eli Lilly)
- Mechanism: Incretin mimetic → stimulates insulin → suppresses appetite → slows digestion
- FDA-approved indication: Type 2 diabetes (Ozempic), Chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity (Wegovy)
- CDSCO approval in India: Semaglutide approved for Type 2 diabetes; weight management indication under review
- Weight loss efficacy: ~10–15% body weight reduction in trials
- Cardiovascular benefit: SELECT trial showed 20% reduction in major cardiovascular events
Connection to this news: The mechanism and proven efficacy of GLP-1 drugs explain the global and Indian demand surge — and frame the regulatory and access debate around a drug class that clearly works but raises questions of equitable access and off-label misuse.
Drug Regulation in India — CDSCO and Approval Process
The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, is India's apex drug regulatory authority — equivalent to the US FDA. It approves new drugs, regulates clinical trials, classifies drugs under various schedules, and enforces manufacturing standards. GLP-1 drugs fall under Schedule H — prescription-only drugs that cannot be sold without a valid doctor's prescription and must be kept in a separate register by pharmacists.
- CDSCO: Established under the Drugs and Cosmetics Act, 1940
- Schedule H drugs: Require prescription; pharmacist must record sale; cannot be advertised to public
- New Drug Approval: Drugs new to India require Phase I/II/III clinical trials or bridging studies; global approval data can be used for expedited review
- Generic drug approval: Requires bioequivalence demonstration with the reference listed drug
- Post-market surveillance: CDSCO's ADR (Adverse Drug Reaction) monitoring network; India has ~250 ADR monitoring centres
Connection to this news: CDSCO's regulatory response — restricting GLP-1 prescriptions to specialists and flagging promotional violations — reflects the challenge of regulating a high-demand drug class as generics flood the market post-patent expiry.
India's NCD Burden — Diabetes and Obesity
India faces a rapidly escalating non-communicable disease (NCD) burden. With approximately 101 million people with Type 2 diabetes (ICMR-INDIAB 2023 data), India is the "diabetes capital of the world." Obesity prevalence is rising sharply, with the NFHS-5 (2019–21) reporting that 24% of women and 23% of men are overweight or obese. The government's national response is the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), which targets diabetes, cardiovascular disease, cancer, and chronic respiratory diseases through district-level screening and treatment at Health and Wellness Centres (HWCs).
- India's diabetes burden: ~101 million (2023, ICMR-INDIAB)
- Obesity prevalence (NFHS-5, 2019–21): ~24% women, ~23% men overweight/obese
- National Programme: NP-NCD (earlier: NPCDCS — National Programme for Cancer, Diabetes, CVD, and Stroke)
- HWC (Health and Wellness Centres): ~1.7 lakh operational; provide free diabetes/hypertension screening
- Ayushman Bharat PM-JAY: Health insurance for ~55 crore beneficiaries; covers hospitalisation but limited outpatient drug coverage
- GLP-1 coverage gap: PM-JAY does not yet cover outpatient semaglutide prescriptions
Connection to this news: India's massive diabetes and obesity burden creates a clear public health case for GLP-1 drugs — but their inclusion in public insurance schemes requires balancing cost, equity, and system capacity.
Pharmaceutical Access and Compulsory Licensing
India's Patents Act, 1970 (as amended in 2005 to comply with TRIPS) contains important access provisions. Section 84 allows any person to apply for a compulsory licence three years after a patent is granted, if the drug is not available at a reasonably affordable price, or the requirements of the public are not met. Section 92 allows the Central Government to grant compulsory licences for a drug "in circumstances of national emergency or extreme urgency" or for "public non-commercial use." The Doha Declaration (2001) on TRIPS and Public Health reaffirmed WTO members' right to use compulsory licensing to address public health emergencies.
- Patents Act, 1970: India's patent law; amended 2005 to include product patents for pharma (post-TRIPS)
- Section 84: Compulsory licence on application (after 3 years)
- Section 92: Government compulsory licence for national emergency/public non-commercial use
- Section 3(d): India's unique provision preventing "evergreening" — bars patents for new forms of known substances without enhanced efficacy
- Doha Declaration (2001): WTO declaration affirming TRIPS flexibilities for public health
- Natco Pharma vs. Bayer (2012): India's first compulsory licence (for sorafenib/Nexavar)
Connection to this news: The semaglutide patent expiry in India (March 2026) makes compulsory licensing moot for this drug. However, the debate illustrates why India's Section 3(d) and compulsory licensing provisions matter for the next generation of expensive drugs — particularly newer obesity drugs still under patent (e.g., tirzepatide).
Key Facts & Data
- Semaglutide patent expiry in India: March 20, 2026
- Generic launches: 40+ Indian companies; first wave includes Dr. Reddy's (Obeda, ~₹4,200/month), Zydus (~₹2,200/month), Alkem (~₹1,800/month)
- Price reduction vs. originator: 70–80% cheaper than Novo Nordisk's branded version
- Regulatory restriction: CDSCO limits prescription to endocrinologists, internal medicine specialists, cardiologists
- Government advisory (March 10, 2026): Stopped misleading advertisements for GLP-1 drugs
- Central directive (March 24, 2026): Flagged unauthorised sales, off-label cosmetic use
- Inspections: 49 businesses inspected (pharmacies, wholesalers, weight loss clinics)
- India's diabetes burden: ~101 million (world's highest absolute count)
- Obesity prevalence: ~24% women, ~23% men overweight/obese (NFHS-5)
- PM-JAY coverage: ~55 crore beneficiaries; GLP-1 outpatient drugs not yet covered
- Key question: Should public insurance (Ayushman Bharat) cover GLP-1 drugs for obesity management?